Compare Stocks: DCOY, INAB, GDTC, and AKTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$7.69 +2.1%	$11.23	$3.02 ▼ $49.60	$8.80M	1.4	338,890 shs	7,345 shs
DCOY Decoy Therapeutics	$3.90 +1.8%	$5.78	$3.51 ▼ $106.20	$2.30M	0.64	183,259 shs	5,844 shs
GDTC CytoMed Therapeutics	$0.85 +5.6%	$1.01	$0.68 ▼ $3.68	$10.00M	0.04	271,002 shs	2,336 shs
INAB IN8bio	$0.99 +1.9%	$1.32	$0.90 ▼ $2.73	$9.80M	0.24	65,398 shs	7,881 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	+7.57%	+2.31%	-45.75%	+146.08%	-80.98%
DCOY Decoy Therapeutics	-2.54%	-11.75%	-35.19%	-25.63%	+382,999,900.00%
GDTC CytoMed Therapeutics	-3.83%	-12.96%	-22.32%	+3.99%	-56.98%
INAB IN8bio	-0.28%	+1.66%	-26.62%	-39.01%	-57.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$7.69 +2.1%	$11.23	$3.02 ▼ $49.60	$8.80M	1.4	338,890 shs	7,345 shs
DCOY Decoy Therapeutics	$3.90 +1.8%	$5.78	$3.51 ▼ $106.20	$2.30M	0.64	183,259 shs	5,844 shs
GDTC CytoMed Therapeutics	$0.85 +5.6%	$1.01	$0.68 ▼ $3.68	$10.00M	0.04	271,002 shs	2,336 shs
INAB IN8bio	$0.99 +1.9%	$1.32	$0.90 ▼ $2.73	$9.80M	0.24	65,398 shs	7,881 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	+7.57%	+2.31%	-45.75%	+146.08%	-80.98%
DCOY Decoy Therapeutics	-2.54%	-11.75%	-35.19%	-25.63%	+382,999,900.00%
GDTC CytoMed Therapeutics	-3.83%	-12.96%	-22.32%	+3.99%	-56.98%
INAB IN8bio	-0.28%	+1.66%	-26.62%	-39.01%	-57.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	2.50	Moderate Buy	$32.33	320.68% Upside
DCOY Decoy Therapeutics	2.00	Hold	$30.00	669.23% Upside
GDTC CytoMed Therapeutics	1.00	Sell	N/A	N/A
INAB IN8bio	2.00	Hold	$4.00	302.41% Upside

Current Analyst Ratings Breakdown

Latest DCOY, INAB, GDTC, and AKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/20/2026	AKTX Akari Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$30.00
7/17/2026	INAB IN8bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	GDTC CytoMed Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/6/2026	AKTX Akari Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/12/2026	DCOY Decoy Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/4/2026	INAB IN8bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/28/2026	DCOY Decoy Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$24.75 per share	N/A
DCOY Decoy Therapeutics	N/A	N/A	N/A	N/A	$11.07 per share	N/A
GDTC CytoMed Therapeutics	$250K	39.99	N/A	N/A	$0.45 per share	1.88
INAB IN8bio	N/A	N/A	N/A	N/A	$2.82 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$17.30M	N/A	N/A	N/A	N/A	N/A	-123.29%	-63.01%	8/18/2026 (Estimated)
DCOY Decoy Therapeutics	-$12.52M	-$106.90	N/A	N/A	N/A	N/A	-395.42%	-193.30%	N/A
GDTC CytoMed Therapeutics	-$3.10M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INAB IN8bio	-$19.44M	-$1.62	N/A	N/A	N/A	N/A	-88.15%	-74.36%	N/A

Latest DCOY, INAB, GDTC, and AKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/18/2026	Q2 2026	AKTX Akari Therapeutics	-$1.04	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	INAB IN8bio	-$0.3437	-$0.25	+$0.0937	-$0.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
DCOY Decoy Therapeutics	N/A	N/A	N/A	N/A	N/A
GDTC CytoMed Therapeutics	N/A	N/A	N/A	N/A	N/A
INAB IN8bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.27	0.27
DCOY Decoy Therapeutics	N/A	1.84	1.84
GDTC CytoMed Therapeutics	0.06	5.17	5.17
INAB IN8bio	N/A	10.50	10.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
DCOY Decoy Therapeutics	11.88%
GDTC CytoMed Therapeutics	0.04%
INAB IN8bio	92.05%

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	32.20%
DCOY Decoy Therapeutics	1.50%
GDTC CytoMed Therapeutics	N/A
INAB IN8bio	14.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	9	1.15 million	776,000	Not Optionable
DCOY Decoy Therapeutics	20	590,000	581,000	N/A
GDTC CytoMed Therapeutics	N/A	11.83 million	N/A	Not Optionable
INAB IN8bio	20	9.86 million	8.43 million	Not Optionable

DCOY, INAB, GDTC, and AKTX Headlines

Recent News About These Companies

FY2029 Earnings Forecast for IN8bio Issued By HC Wainwright

August 10 at 1:58 AM | americanbankingnews.com

IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 6, 2026 | finance.yahoo.com

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

July 9, 2026 | globenewswire.com

Analysts Are Bullish on Top Healthcare Stocks: Corvus Pharmaceuticals (CRVS), IN8bio (INAB)

July 8, 2026 | theglobeandmail.com

IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

June 4, 2026 | zacks.com

IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T ...

June 3, 2026 | caledonianrecord.comC

IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies

June 3, 2026 | globenewswire.com

In8bio (INAB) Stock Forecast & Price Target

June 2, 2026 | investing.com

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

June 1, 2026 | globenewswire.com

IN8bio launches new JonesTrading at-the-market program

June 1, 2026 | tipranks.com

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and IN8bio (INAB)

May 23, 2026 | theglobeandmail.com

IN8bio, Inc: IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 8, 2026 | finanznachrichten.de

IN8bio Reports Q1 2026 Results and Shareholder Votes

May 7, 2026 | tipranks.com

IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 7, 2026 | globenewswire.com

IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences

May 6, 2026 | globenewswire.com

IN8bio (INAB) Gets a Buy from JonesTrading

April 16, 2026 | theglobeandmail.com

IN8bio Insider Trading Activity | NASDAQ:INAB | Benzinga

April 10, 2026 | benzinga.com

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 3, 2026 | globenewswire.com

IN8bio (INAB) price target decreased by 87.27% to 6.46

March 29, 2026 | msn.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Korro Bio (KRRO), IN8bio (INAB) and Aveanna Healthcare Holdings (AVAH)

March 15, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DCOY, INAB, GDTC, and AKTX Company Descriptions

Akari Therapeutics NASDAQ:AKTX

$7.69 +0.16 (+2.07%)

As of 10:40 AM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Decoy Therapeutics NASDAQ:DCOY

$3.90 +0.07 (+1.83%)

As of 10:38 AM Eastern

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

CytoMed Therapeutics NASDAQ:GDTC

$0.84 +0.04 (+5.61%)

As of 10:32 AM Eastern

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

IN8bio NASDAQ:INAB

$0.99 +0.02 (+1.85%)

As of 10:27 AM Eastern

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DCOY, INAB, GDTC, and AKTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DCOY, INAB, GDTC, and AKTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DCOY, INAB, GDTC, and AKTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DCOY, INAB, GDTC, and AKTX Company Descriptions

Akari Therapeutics NASDAQ:AKTX

Decoy Therapeutics NASDAQ:DCOY

CytoMed Therapeutics NASDAQ:GDTC

IN8bio NASDAQ:INAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DCOY, INAB, GDTC, and AKTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DCOY, INAB, GDTC, and AKTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DCOY, INAB, GDTC, and AKTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DCOY, INAB, GDTC, and AKTX Company Descriptions

Akari Therapeutics NASDAQ:AKTX

Decoy Therapeutics NASDAQ:DCOY

CytoMed Therapeutics NASDAQ:GDTC

IN8bio NASDAQ:INAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools